Investigation on Brazilian Clinical Practices in Rheumatoid Arthritis the Brazilian Rheumatoid Arthritis Clinical Practices Investigation-BRACTICE

dc.contributor.authorHelfenstein Junior, Milton [UNIFESP]
dc.contributor.authorRadu Halpern, Ari Stiel
dc.contributor.authorBertolo, Manoel Barros
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionHosp Israelita Albert Einstein
dc.contributor.institutionUniversidade Estadual de Campinas (UNICAMP)
dc.date.accessioned2016-01-24T14:16:51Z
dc.date.available2016-01-24T14:16:51Z
dc.date.issued2011-06-01
dc.description.abstractRheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease causing significant social, medical, and economic impact. Several therapeutic regimens are available within the medical arsenal. the rational and reasoned use of various medications approved for their treatment is imperative. This study aimed to evaluate how Brazilian rheumatologists use the drugs available to combat the disease.For this, 128 Brazilian rheumatologists from public and private health services responded to an 18-item questionnaire, sent over the Internet, about different situations of drug treatment of RA. the answers helped to confirm the trends among Brazilian rheumatologists in the drug treatment of RA.The study results have shown that most Brazilian rheumatologists follow the guidelines and consensus established by the Brazilian Society of Rheumatology for the treatment of RA. A small proportion, however, start the biologic therapy in early stages of the disease, including the very early stage, as the first treatment option. Most experts use corticosteroids in low doses early in the treatment.Conclusions: This study confirms that the majority but not all Brazilian rheumatologists follow, in their daily practice, established guidelines and consensus for the treatment of RA. However, it also shows that some few rheumatologists start with anti-tumor necrosis factor therapy in very early arthritis independently of disease severity or prognostic factors.en
dc.description.affiliationUniversidade Federal de São Paulo, Escola Paulista Med, BR-04707010 São Paulo, Brazil
dc.description.affiliationUniv São Paulo, Fac Med, Hosp Clin, BR-05508 São Paulo, Brazil
dc.description.affiliationHosp Israelita Albert Einstein, São Paulo, Brazil
dc.description.affiliationUniv Estadual Campinas, Fac Ciencias Med, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Escola Paulista Med, BR-04707010 São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipSanofi Aventis
dc.format.extentS1-S10
dc.identifierhttp://dx.doi.org/10.1097/RHU.0b013e3182224ea4
dc.identifier.citationJcr-Journal of Clinical Rheumatology. Philadelphia: Lippincott Williams & Wilkins, v. 17, n. 4, p. S1-S10, 2011.
dc.identifier.doi10.1097/RHU.0b013e3182224ea4
dc.identifier.issn1076-1608
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/33780
dc.identifier.wosWOS:000291383400001
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJcr-Journal of Clinical Rheumatology
dc.rightsAcesso restrito
dc.subjectrheumatoid arthritisen
dc.subjectdrug treatmenten
dc.subjectconsensusen
dc.subjectguidelinesen
dc.titleInvestigation on Brazilian Clinical Practices in Rheumatoid Arthritis the Brazilian Rheumatoid Arthritis Clinical Practices Investigation-BRACTICEen
dc.typeArtigo
Arquivos